Anticoagulants market forecast to hit $97.07 billion by 2030

By AI, Created 10:58 AM UTC, May 20, 2026, /AGP/ – The global anticoagulants market is projected to climb from $53.88 billion in 2025 to $60.42 billion in 2026, then reach $97.07 billion by 2030, according to The Business Research Company. Rising cardiovascular disease, more atrial fibrillation patients and wider use of direct oral anticoagulants are driving demand across hospitals and outpatient care.

Why it matters: - The anticoagulants market sits at the center of cardiovascular care, where blood clot prevention helps reduce stroke, heart attack and other serious complications. - Market growth signals rising demand for therapies that manage venous thromboembolism, atrial fibrillation and other clot-related conditions. - The expansion also reflects a broader shift toward safer, easier-to-use oral treatments in both hospital and outpatient settings.

What happened: - The Business Research Company said the global anticoagulants market reached $53.88 billion in 2025 and is expected to rise to $60.42 billion in 2026. - The report projects the market will grow to $97.07 billion by 2030. - The company released its Anticoagulants Global Market Report 2026 on May 7, 2026, from London. - The report provides market size, trends and forecasts for 2026-2035. - A free sample report is available. - The full anticoagulants market report is available online.

The details: - The market is forecast to grow at a 12.1% compound annual growth rate from 2025 to 2026. - The report forecasts a 12.6% CAGR through 2030. - Growth drivers in the near term include rising cardiovascular disease rates, more venous thromboembolism cases, the long use of warfarin, growth in hospital-based treatment and greater awareness of stroke prevention. - Longer-term growth is expected to come from more atrial fibrillation patients, higher use of factor Xa inhibitors, stronger safety profiles for novel oral anticoagulants and wider outpatient anticoagulation management. - Rising adoption in emerging economies is also part of the forecast. - Anticoagulants are medications used to prevent and treat blood clots in the heart and blood vessels. - The drugs are often called blood thinners, though they work by slowing clotting rather than thinning blood. - Proper use can help prevent thrombosis and reduce the risk of stroke and heart attacks. - The report identifies a shift toward direct oral anticoagulants, a move from injectable to oral forms and greater use of long-term therapy. - The report also points to more emphasis on patient adherence, safety and preventive cardiovascular care. - North America held the largest share of the anticoagulants market in 2025. - The report also covers Asia-Pacific, South East Asia, Western and Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests anticoagulant demand is becoming more tied to chronic disease management than to short-term inpatient use alone. - The emphasis on oral therapies and outpatient management points to care models that are easier for patients and health systems to scale. - The rising burden of cardiovascular disease in aging populations appears to be the clearest structural driver behind the market’s growth path.

What’s next: - Market growth will likely track diagnosis rates, treatment adoption and access to newer oral anticoagulants through 2030. - The report points to continued momentum in emerging economies and broader preventive cardiovascular use. - More information is available in related reports on the anticoagulant market, antivenom market and antithrombotic drugs market.

The bottom line: - The anticoagulants market is on a strong growth path, powered by rising cardiovascular disease and a clear shift toward oral, outpatient-friendly therapies.